Tennessee SB 2097: Insurance, Health, Accident - As introduced, requires certain insurers with policies or contracts that provide coverage for Veklury (remdesivir) to also provide coverage for monoclonal antibody infusions and budesonide treatment at a cost to the insured no greater than the cost of Veklury (remdesivir) to the insured on or after July 1, 2022. - Amends TCA Title 8; Title 56 and Title 71.

Status: Recalled from Senate Commerce & Labor Committee (as of 2022-02-25)

State: Tennessee · Session: 112 · Bill: SB 2097

Subjects: Accident, Health, Insurance

Sponsors: Pody

View Tennessee SB 2097 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.